Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Scholar Rock Holding Corporation SRRK
$7.95
-$0.09 (-1.12%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
438673704.00000000
-
week52high
13.00
-
week52low
4.33
-
Revenue
33193000
-
P/E TTM
-3
-
Beta
0.76710900
-
EPS
-2.35000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 10:59
Описание компании
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| BMO Capital | Outperform | Outperform | 09 авг 2022 г. |
| Truist Securities | Buy | 12 июл 2022 г. | |
| Piper Sandler | Overweight | Overweight | 23 июн 2022 г. |
| JP Morgan | Overweight | Overweight | 24 мая 2022 г. |
| Piper Sandler | Overweight | Overweight | 17 мая 2022 г. |
| BMO Capital | Outperform | Outperform | 15 ноя 2022 г. |
| JP Morgan | Overweight | Overweight | 18 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Myles Edward H | D | 147179 | 7043 | 17 янв 2023 г. |
| Ho Junlin | D | 116062 | 4529 | 17 янв 2023 г. |
| Parlavecchio Caryn | D | 75715 | 2934 | 17 янв 2023 г. |
| Invus Public Equities, L.P. | D | 9027950 | 1094 | 09 янв 2023 г. |
| Invus Public Equities, L.P. | A | 9029044 | 48774 | 05 янв 2023 г. |
| Marantz Jing L. | A | 250000 | 250000 | 14 ноя 2022 г. |
| Invus Public Equities, L.P. | A | 8980270 | 130265 | 25 окт 2022 г. |
| Invus Public Equities, L.P. | A | 8850005 | 66000 | 04 окт 2022 г. |
| Invus Public Equities, L.P. | A | 8784005 | 33971 | 03 окт 2022 г. |
| Backstrom Jay T. | A | 1000000 | 1000000 | 20 сент 2022 г. |
Новостная лента
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Business Wire
01 мар 2023 г. в 08:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced it will present data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment with apitegromab, an investigational selective inhibitor of the activation of myostatin for spinal muscular atrophy (SMA).
Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference
Business Wire
27 февр 2023 г. в 08:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 12:50 p.m. ET.
Scholar Rock to Participate in Upcoming Investor Conferences
Business Wire
08 ноя 2022 г. в 08:00
CAMBRIDGE, Mass.
Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy
Seeking Alpha
20 окт 2022 г. в 10:03
Shares are down 70% thus far in 2022. TOPAZ data update for apitegromab in SMA was encouraging (as reflected in increases in HFMSE and RULM scores).
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit
Business Wire
16 сент 2022 г. в 08:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit